Treatment Results of Capecitabine Metronomic Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma after Standard Chemoradiotherapy– A Single- Arm Phase II Study | ||
| SECI Oncology Journal | ||
| Volume 11, Issue 1, January 2023, Pages 82-88 | ||
| Abstract | ||
| Background: High recurrence risk exists for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) thus adjuvant therapies are required to lower the risk of recurrence and mortality. This phase II trial was designed for evaluating the effectiveness and safety of adding metronomic capecitabine as an adjuvant therapy to chemoradiation in patients with locally advanced NPC. Methods: This prospective single-arm phase II single trial involved 41 patients aged from 18 to 75 years, with locally advanced NPC (Stage III - Stage IVA) with no previous treatment or distant metastases at diagnosis. Oral metronomic capecitabine (Xeloda; 650 mg/m² body surface area was administered twice daily for 1 year. Clinical or imaging exams were conducted. Individuals were assessed to have had a full response when they showed no recorded signs of the disease following the completion of therapy and were free from disease for three months at least. The duration of follow-up was for 24 months. Results: Locoregional recurrence was developed in 6 (14.63%). Rates of twoyear overall survival (OS) for all patients (n = 41) in this trial was 92.68%, the 2-year disease free survival (DFS) rate for them was 85.37% and progression free survival (PFS) was 78.05%. Conclusions: Metronomic chemotherapy with capecitabine was a promising treatment for patients with locally advanced NPC. The 2-year OS and PFS were improved, and the acute and late toxicities were tolerated. | ||
| Keywords | ||
| Capecitabine Metronomic; Locally Advanced Nasopharyngeal Carcinoma; Standard Chemoradiotherapy | ||
|
Supplementary Files
|
||
|
Statistics Article View: 89 |
||
